These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24884319)

  • 1. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
    Palumbo A; Offidani M; Patriarca F; Petrucci MT; Cavo M
    Leuk Lymphoma; 2015 Mar; 56(3):559-67. PubMed ID: 24884319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine in multiple myeloma.
    Gentile M; Vigna E; Recchia AG; Morabito L; Mendicino F; Giagnuolo G; Morabito F
    Eur J Haematol; 2015 Nov; 95(5):377-88. PubMed ID: 26085055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
    Pratt G; Bowcock S; Lai M; Bell S; Bird J; D'Sa S; Cavenagh J; Cook G; Morgan G; Owen R; Snowden JA; Yong K; Davies F;
    Int J Lab Hematol; 2014 Feb; 36(1):20-8. PubMed ID: 23615178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
    Stöhr E; Schmeel FC; Schmeel LC; Hänel M; Schmidt-Wolf IG;
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2205-12. PubMed ID: 26156122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
    Musto P; Fraticelli VL; Mansueto G; Madonna E; Nozza A; Andriani A; Mussetti A; Ballanti S; Bongarzoni V; Baraldi A; Patriarca F; Vincelli D; Falcone A; Derudas D; Califano C; Zambello R; Mele G; Fragasso A; Baldini L; Storti S
    Leuk Lymphoma; 2015 May; 56(5):1510-3. PubMed ID: 25651428
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
    Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
    Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bendamustine in the management of plasma cell myeloma.
    Gertz MA
    Leuk Lymphoma; 2015 May; 56(5):1195-6. PubMed ID: 25347428
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
    Damaj G; Malard F; Hulin C; Caillot D; Garidi R; Royer B; Marit G; Stoppa AM; Banos A; Morineau N; Moreau P; Fitoussi O; Tiab M; Moreau P
    Leuk Lymphoma; 2012 Apr; 53(4):632-4. PubMed ID: 21916831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
    Gomez-Arteaga A; Mark TM; Guarneri D; Christos PJ; Gergis U; Greenberg JD; Hsu J; Mayer SA; Niesvizky R; Pearse RN; Phillips AA; Rossi A; Coleman M; van Besien K; Shore TB
    Bone Marrow Transplant; 2019 Dec; 54(12):2027-2038. PubMed ID: 31190006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.
    Lee HC; Feng L; Oriabure O; Graham V; Chen W; Badillo M; Lu R; Lee HJ; Jain P; Manasanch EE; Orlowski RZ; Wang ML
    Am J Hematol; 2021 Jul; 96(7):E243-E246. PubMed ID: 33811767
    [No Abstract]   [Full Text] [Related]  

  • 14. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC; Colman H; Kim BT; Raizer J
    J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
    Breitkreutz I; Becker N; Benner A; Kosely F; Heining C; Hillengass J; Egerer G; Ho AD; Goldschmidt H; Raab MS
    Hematol Oncol; 2016 Dec; 34(4):200-207. PubMed ID: 25784529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine: mechanism of action and clinical data.
    Cheson BD; Leoni L
    Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 19):1-11. PubMed ID: 22362008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives.
    Costa BA; Mouhieddine TH; Ortiz RJ; Richter J
    Crit Rev Oncol Hematol; 2023 Jul; 187():104040. PubMed ID: 37244325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine in the treatment of multiple myeloma: results and future perspectives.
    Pönisch W; Niederwieser D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):23-6. PubMed ID: 12170429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
    Yalnız FF; Akkoç N; Salihoğlu A; Ar MC; Öngören Ş; Eşkazan AE; Soysal T; Aydın Y
    Turk J Haematol; 2017 Aug; 34(3):233-238. PubMed ID: 28270368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.